Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G8NN
|
||||
| Former ID |
DAP000019
|
||||
| Drug Name |
Pramipexole
|
||||
| Synonyms |
Mirapex; Pramipexol; Pramipexolum; SUD919CL2Y; Mirapex (TN); Mirapexin (TN); Pramipexole [USAN:INN]; SND-919; Sifrol(TN); U-98528E; Pramipexole (USAN/INN); (-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antiparkinson Agents
|
||||
| Company |
Intas Pharma
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H17N3S
|
||||
| InChI |
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
|
||||
| InChIKey |
FASDKYOPVNHBLU-ZETCQYMHSA-N
|
||||
| CAS Number |
CAS 104632-26-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7980372, 10633207, 11342091, 11362274, 11364752, 11367314, 11369876, 11378041, 11487676, 11495652, 14748917, 14797724, 26719739, 29300417, 46386856, 46505897, 47207239, 47589086, 48416455, 49681584, 49890661, 50112695, 56464131, 57309747, 57339564, 75921463, 91615696, 92308251, 92309051, 93166408, 99431914, 103245538, 104010405, 104408638, 118317775, 124658831, 124800011, 127818967, 131293470, 135017226, 135650847, 137055231, 137205527, 142970931, 144205998, 160831530, 162038142, 163094982, 163392621, 164216289
|
||||
| ChEBI ID |
ChEBI:8356
|
||||
| SuperDrug ATC ID |
N04BC05
|
||||
| SuperDrug CAS ID |
cas=104632260
|
||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Modulator | [3] | |
| D(2) dopamine receptor | Target Info | Modulator | [3] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Dopaminergic synapsehsa04015:Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| References | |||||
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 953). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.